-transparent.png){kind=logo}
As part of an effort to develop peptides with selective kappa-opioid antagonist activity, a series of N-alkylated [D-Pro10]dynorphin A-(1-11) derivatives were made through solid-phase peptide synthesis: R-Tyr-Gly-Gly-Phe-Leu-Arg-Arg-Ile-Arg-D-Pro-LysOH, where R = N-benzyl, N-cyclopropylmethyl, N,N-dicyclopropylmethyl, or N,N-diallyl. These derivatives and dynorphin A-(1-13)NH2 were evaluated for kappa-opioid receptor binding affinity and potency as inhibitors of adenylyl cyclase. Equilibrium competition binding experiments using [3H]diprenorphine (approximately 600 pM) were performed on membranes prepared from cultured Chinese hamster ovary (CHO) cells stably expressing the rat kappa-opioid receptor. Tissue prepared from this cell line was used to evaluate opioid peptide inhibition of forskolin-stimulated (50 microM) adenylyl cyclase activity. Displacement of [3H]diprenorphine specific binding by these peptides was observed with a rank order of affinity (Ki, nM) = [D-Pro10]dynorphin A-(1-11) (0.13) > dynorphin A-(1-13)NH2 (0.34) > N-cyclopropylmethyl- (1.4) > N,N-dicyclopropylmethyl- (12.6) approximately N-benzyl- (18.3) approximately N,N-diallyl-[D-Pro10]dynorphin A-(1-11) (26.0). A similar rank order was observed for potency of adenylyl cyclase inhibition (IC50, nM): [D-Pro10]dynorphin A-(1-11) (0.12) approximately dynorphin A-(1-13)NH2 (0.19) > N-cyclopropylmethyl- (2.7) > N,N-dicyclopropylmethyl- (13.2) approximately N,N-diallyl- (18.0) approximately N-benzyl-[D-Pro10]dynorphin A-(1-11) (36.4). The peptides differed in their percent maximal inhibition of adenylyl cyclase activity: dynorphin A-(1-13)NH2 (100%) approximately N-cyclopropylmethyl- (94.3%) approximately [D-Pro10]dynorphin A-(1-11) (87.9%) > N-benzyl- (71.4%) >> N,N-dicyclopropylmethyl- (23.6%) approximately N,N-diallyl-[D-Pro10]dynorphin A-(1-11)(18.9%). As the N,N-dicyclopropylmethyl- and N,N-diallyl-[D-Pro10]dynorphin A-(1-11) derivatives were found to have only weak partial agonist activity with respect to adenylyl cyclase inhibition, they were evaluated for their ability to reverse dynorphin A-(1-13)NH2 (10 nM) inhibition of adenylyl cyclase activity. N,N-dicyclopropylmethyl- and N,N-diallyl-[D-Pro10]dynorphin A-(1-11) reversed dynorphin A-(1-13)NH2 inhibition to levels equal to the maximal inhibition produced by N,N-dicyclopropylmethyl- and N,N-diallyl-[D-Pro10]dynorphin A-(1-11) alone. This weak partial agonism combined with nanomolar potency render the N,N-dicyclopropylmethyl- and N,N-diallyl-[D-Pro10]dynorphin A-(1-11) compounds promising leads for further attempts to synthesize peptide kappa-opioid receptor antagonists.
K Soderstrom, and
H Choi, and
F W Berman, and
J V Aldrich, and
T F Murray
November 1992,
Journal of medicinal chemistry,
K Soderstrom, and
H Choi, and
F W Berman, and
J V Aldrich, and
T F Murray
June 1988,
The Journal of pharmacology and experimental therapeutics,
K Soderstrom, and
H Choi, and
F W Berman, and
J V Aldrich, and
T F Murray
December 1988,
British journal of pharmacology,
K Soderstrom, and
H Choi, and
F W Berman, and
J V Aldrich, and
T F Murray
January 1988,
Proceedings of the National Academy of Sciences of the United States of America,
K Soderstrom, and
H Choi, and
F W Berman, and
J V Aldrich, and
T F Murray
November 1984,
European journal of pharmacology,
K Soderstrom, and
H Choi, and
F W Berman, and
J V Aldrich, and
T F Murray
August 1997,
Journal of medicinal chemistry,
K Soderstrom, and
H Choi, and
F W Berman, and
J V Aldrich, and
T F Murray
February 1986,
Biochemical and biophysical research communications,
K Soderstrom, and
H Choi, and
F W Berman, and
J V Aldrich, and
T F Murray
January 1986,
NIDA research monograph,
K Soderstrom, and
H Choi, and
F W Berman, and
J V Aldrich, and
T F Murray
January 1983,
Life sciences,
K Soderstrom, and
H Choi, and
F W Berman, and
J V Aldrich, and
T F Murray
January 1983,
European journal of pharmacology,
